Trials / Completed
CompletedNCT02246673
RDEA3170 and Febuxostat Combination Study in Gout Subjects
A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to Febuxostat Administered Alone in Adult Subjects With Gout
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Ardea Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDEA3170 15 mg | |
| DRUG | RDEA3170 10 mg | |
| DRUG | RDEA3170 2.5 | |
| DRUG | RDEA3170 5 mg | |
| DRUG | Febuxostat 40 mg | |
| DRUG | Febuxostat 80 mg |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-07-01
- Completion
- 2016-02-01
- First posted
- 2014-09-23
- Last updated
- 2017-07-27
- Results posted
- 2017-07-27
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02246673. Inclusion in this directory is not an endorsement.